McQuade Center, Sentinel Oncology Working on New Therapy

McQuade Center, Sentinel Oncology Working on New Therapy

307219

McQuade Center, Sentinel Oncology Working on New Therapy

The McQuade Center for Strategic Research and Development (MSRD) will collaborate with Sentinel Oncology for the clinical development of a potential breakthrough treatment for fragile X syndrome (FXS). Under agreement terms, the MSRD, which funds innovative early stage research and development programs, will work with the United Kingdom-based treatment discovery company Sentinel to advance investigational compound SOL784 to Phases 1a and 1b clinical trials. Those studies may be followed by an expanded collaboration, according to a…

You must be logged in to read/download the full post.